Michael Barbella, Managing Editor01.29.22
Financial news has consistently drawn visitors to MPO's website and this past week was no exception. Traffic was driven by J&J Medical Devices' stellar earnings report, Venus Medtech's equity interest deal with Cardiovalve, and Titan Medical's final milestone payment from Medtronic.
J&J's Medical Devices division reported a 17.9 percent jump in revenue last year, driven by a recovery from pandemic-related impacts and associated medical procedure deferrals that previously curtailed volume (and proceeds) in the Surgery, Interventional Solutions, Vision, and Orthopaedics franchises. Fourth-quarter 2021 medical device sales rose 4.1 percent to $6.85 billion, and J&J's overall global revenue swelled 10.4 percent to $24.8 billion. The company's one-shot COVID-19 vaccine generated $1.62 billion in sales during Q4 (ended Dec. 31, 2021), or more than double the previous quarter's total.
Venus Medtech generated website traffic as well by completing its 100 percent equity interest in Israeli transcatheter mitral and tricuspid valve treatment firm Cardiovalve. The latter entity is now a member of Venus Medtech's global operations team.
News of Titan Medical's final milestone payment from Medtronic intrigued website viewers, too. The company received an $8.3 million payment from Medtronic under development and licensing agreements that began in 2020 to advance robotic-assisted surgical technologies for use by both organizations.
Other stories attracting readers included the top five technology trends this year for the medical device industry and the positive results from Intersect ENT's study of its Propel sinus implant.
1. The Top Five Technology Trends for the Medical Device Industry in 2022
2. J&J Medical Devices Biz Achieves Double-Digit Growth in 2021
3. Intersect ENT Reports Positive Results in Study of Propel Sinus Implant
4. Venus Medtech Completes Equity Interest Deal with Cardiovalve
J&J's Medical Devices division reported a 17.9 percent jump in revenue last year, driven by a recovery from pandemic-related impacts and associated medical procedure deferrals that previously curtailed volume (and proceeds) in the Surgery, Interventional Solutions, Vision, and Orthopaedics franchises. Fourth-quarter 2021 medical device sales rose 4.1 percent to $6.85 billion, and J&J's overall global revenue swelled 10.4 percent to $24.8 billion. The company's one-shot COVID-19 vaccine generated $1.62 billion in sales during Q4 (ended Dec. 31, 2021), or more than double the previous quarter's total.
Venus Medtech generated website traffic as well by completing its 100 percent equity interest in Israeli transcatheter mitral and tricuspid valve treatment firm Cardiovalve. The latter entity is now a member of Venus Medtech's global operations team.
News of Titan Medical's final milestone payment from Medtronic intrigued website viewers, too. The company received an $8.3 million payment from Medtronic under development and licensing agreements that began in 2020 to advance robotic-assisted surgical technologies for use by both organizations.
Other stories attracting readers included the top five technology trends this year for the medical device industry and the positive results from Intersect ENT's study of its Propel sinus implant.